CareDx Inc (CDNA)vsDanaher Corporation (DHR)
CDNA
CareDx Inc
$47.31
+0.17%
HEALTHCARE · Cap: $2.35B
DHR
Danaher Corporation
$205.84
-0.80%
HEALTHCARE · Cap: $125.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 5381% more annual revenue ($25.11B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs 16.0%. CDNA trades at a lower P/E of 22.6x. DHR earns a higher WallStSmart Score of 66/100 (B-).
CDNA
Buy53
out of 100
Grade: C-
DHR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.3%
Fair Value
$62.15
Current Price
$47.31
$14.84 discount
Margin of Safety
-77.6%
Fair Value
$117.88
Current Price
$205.84
$87.96 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Operating Margin, Return on Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
CDNA profiles as a growth stock while DHR is a mature play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.42 — expect wider price swings.
CDNA is growing revenue faster at 52.2% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 53/100), backed by strong 16.0% margins. CDNA offers better value entry with a 68.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?